Ki saves life: new diagnostic tools for aggressive forms of cancer!

Ki saves life: new diagnostic tools for aggressive forms of cancer!

Laimgrubengasse 10, 1060 Wien, Österreich - The Menarini Group, an international pharmaceutical and diagnostic company based in Florence and New York, has announced a pioneering partnership with Visualdx to improve the early detection of blastic plasma cyties dendritic neoplasia (BPDCN). These trophic skin diseases that are assigned to one of the most dangerous types of cancer show classic signs in the form of skin lesions. The new cooperation focuses on implementing artificial intelligence (AI) and machine learning (ML) to enable doctors to faster and more precise diagnostics, as the Menarini Group carried out. The innovative tool is used by more than 2,300 health facilities worldwide to support medical specialists in diagnosing skin problems so that patients can receive adequate treatment faster.

bpdcn is an aggressive hematological malignant that comes from the group of rare cancer and historically has a bad prognosis - the survival time after the diagnosis is only about 8 to 14 months. The only approved drug for treatment is TAGRAXFUSP ores, which can significantly increase the chances of survival for patients if the disease is recognized early. Dr. Marina Konopleva, an expert in this area, emphasizes that the quick diagnosis is vital for survival in order to be able to initiate effective treatments before the patient's condition deteriorates. The VisUaldx tool uses current image data and AI technologies to support dermatologists in identifying and biopsy suspicious lesions.

risks and important information about Elzonris

As reported by Elzonris.com, treatment with Elzonris, the medication against BPDCN, seriously risks such as capillary leak syndrome (CLS), in which liquid exits blood vessels and causes potentially life -threatening symptoms. Patients have to pay attention to signs such as sudden weight gain and breathing difficulties. The most common side effects are nausea, fatigue and weight gain, with almost half of all the signs of liver problems treated. It is crucial that doctors and patients continuously monitor the symptoms in order to recognize more serious complications at an early stage and to adapt the treatment if necessary.